Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Buy” from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been assigned an average rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $43.17.

Several research analysts have recently weighed in on ORKA shares. Stifel Nicolaus started coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Monday, November 25th. TD Cowen started coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating on the stock. Lifesci Capital initiated coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Finally, Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $21.20 on Monday. The stock has a market cap of $741.98 million, a price-to-earnings ratio of -3.39 and a beta of 0.78. Oruka Therapeutics has a 1-year low of $18.20 and a 1-year high of $53.88. The company’s fifty day moving average is $25.31.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ORKA. Franklin Resources Inc. purchased a new stake in Oruka Therapeutics in the 3rd quarter worth about $17,661,000. Geode Capital Management LLC bought a new position in Oruka Therapeutics in the 3rd quarter valued at $343,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at $11,699,000. Wellington Management Group LLP bought a new position in shares of Oruka Therapeutics in the third quarter worth about $2,013,000. Finally, RTW Investments LP bought a new stake in Oruka Therapeutics during the 3rd quarter valued at about $45,359,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.